These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 10121070)

  • 1. Sporicidin responds to the recall of its products.
    Healthc Hazard Mater Manage; 1992 Aug; 5(11):8-11. PubMed ID: 10121070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Sporicidin recall.
    Healthc Hazard Mater Manage; 1992 Jan; 5(4):9-11. PubMed ID: 10116667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sporicidin update: are the government's regulatory teeth tearing a hole in industry?
    Healthc Hazard Mater Manage; 1993 Apr; 6(7):10-1. PubMed ID: 10125098
    [No Abstract]   [Full Text] [Related]  

  • 4. Applications for Food and Drug Administration application approval to market a new drug; revision of postmarketing reporting requirements. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2007 Oct; 72(201):58993-9000. PubMed ID: 17966558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Applications for Food and Drug Administration approval to market a new drug; postmarketing reports; reporting information about authorized generic drugs. Direct final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Sep; 73(189):56487-91. PubMed ID: 18985960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FDA attempting to overcome major roadblocks in monitoring drug safety.
    Zielinski SL
    J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
    [No Abstract]   [Full Text] [Related]  

  • 7. Federal regulatory action against sporicidin cold sterilizing solution.
    Centers for Disease Control (CDC)
    MMWR Morb Mortal Wkly Rep; 1991 Dec; 40(50):880-1. PubMed ID: 1749372
    [No Abstract]   [Full Text] [Related]  

  • 8. FDA tightens its grip on drug regulation.
    Coombes R
    BMJ; 2007 Feb; 334(7588):290-1. PubMed ID: 17289729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Prescription Drug User Fee Act: is a faster Food and Drug Administration always a better Food and Drug Administration?
    Zelenay JL
    Food Drug Law J; 2005; 60(2):261-338. PubMed ID: 16094773
    [No Abstract]   [Full Text] [Related]  

  • 10. Cause and effect? Assessing postmarketing safety studies as evidence of causation in products liability cases.
    Shea LL; Hanson A; Guglielmetti TM; Levy K
    Food Drug Law J; 2007; 62(3):445-72. PubMed ID: 17915388
    [No Abstract]   [Full Text] [Related]  

  • 11. Regulators scramble to tighten loopholes after heparin debacle.
    Jia H
    Nat Biotechnol; 2008 May; 26(5):477-8. PubMed ID: 18464756
    [No Abstract]   [Full Text] [Related]  

  • 12. New glutaraldehyde labeling controversial.
    Patterson P
    OR Manager; 1995 Sep; 11(9):26. PubMed ID: 10144942
    [No Abstract]   [Full Text] [Related]  

  • 13. Blowing the whistle at the FDA.
    Simons J
    Fortune; 2005 Jan; 151(2):32. PubMed ID: 15693304
    [No Abstract]   [Full Text] [Related]  

  • 14. Tougher glutaraldehyde requirements: what CS technicians need to know.
    Swenson D
    Mater Manag Health Care; 1993 May; 2(5):36, 38-9. PubMed ID: 10125746
    [No Abstract]   [Full Text] [Related]  

  • 15. List of drug products that have been withdrawn or removed from the market for reasons of safety or effectiveness--FDA. Proposed rule.
    Fed Regist; 1998 Oct; 63(195):54082-9. PubMed ID: 10185826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. US Senate passes FDA Revitalization Act.
    Guthrie P
    CMAJ; 2007 Jul; 177(1):23. PubMed ID: 17606930
    [No Abstract]   [Full Text] [Related]  

  • 17. The impact of FDA reform.
    Trunzo J
    Med Device Technol; 2003 Apr; 14(3):36-7. PubMed ID: 12789699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Postmarketing studies for approved human drug and licensed biological products; status reports. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 2000 Oct; 65(210):64607-19. PubMed ID: 11503687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug safety: a contrarian's point of view.
    Cobert B
    Food Drug Law J; 2007; 62(3):501-12. PubMed ID: 17915392
    [No Abstract]   [Full Text] [Related]  

  • 20. Ensuring the safety of genotech drugs through implied warranty theory.
    Serra WM
    Am J Law Med; 1997; 23(2-3):363-81. PubMed ID: 9262761
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.